- Home
- AUPH vs OCS Comparison
AUPH vs OCS Comparison
Compare AUPH & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUPH
- OCS
- Stock Information
- Founded
- AUPH 1993
- OCS 2003
- Country
- AUPH Canada
- OCS Switzerland
- Employees
- AUPH N/A
- OCS N/A
- Industry
- AUPH Biotechnology: Pharmaceutical Preparations
- OCS Biotechnology: Pharmaceutical Preparations
- Sector
- AUPH Health Care
- OCS Health Care
- Exchange
- AUPH Nasdaq
- OCS Nasdaq
- Market Cap
- AUPH 1.1B
- OCS 1.0B
- IPO Year
- AUPH 1999
- OCS N/A
- Fundamental
- Price
- AUPH $8.77
- OCS $19.22
- Analyst Decision
- AUPH Strong Buy
- OCS Strong Buy
- Analyst Count
- AUPH 2
- OCS 3
- Target Price
- AUPH $11.50
- OCS $35.33
- AVG Volume (30 Days)
- AUPH 1.4M
- OCS 27.3K
- Earning Date
- AUPH 07-31-2025
- OCS 08-26-2025
- Dividend Yield
- AUPH N/A
- OCS N/A
- EPS Growth
- AUPH N/A
- OCS N/A
- EPS
- AUPH 0.27
- OCS N/A
- Revenue
- AUPH $247,295,000.00
- OCS $847,333.00
- Revenue This Year
- AUPH $12.15
- OCS $18.70
- Revenue Next Year
- AUPH $18.31
- OCS $1,059.78
- P/E Ratio
- AUPH $31.76
- OCS N/A
- Revenue Growth
- AUPH 29.20
- OCS N/A
- 52 Week Low
- AUPH $5.20
- OCS $10.79
- 52 Week High
- AUPH $10.67
- OCS $23.08
- Technical
- Relative Strength Index (RSI)
- AUPH 66.00
- OCS 53.13
- Support Level
- AUPH $7.71
- OCS $18.98
- Resistance Level
- AUPH $8.29
- OCS $19.75
- Average True Range (ATR)
- AUPH 0.25
- OCS 0.52
- MACD
- AUPH 0.03
- OCS -0.06
- Stochastic Oscillator
- AUPH 84.40
- OCS 48.00
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.